Analyzing Crescent Biopharma (NASDAQ:CBIO) and XTL Biopharmaceuticals (NASDAQ:XTLB)

XTL Biopharmaceuticals (NASDAQ:XTLB) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Valuation & Earnings

This table compares XTL Biopharmaceuticals and Crescent Biopharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450,000.00	11.96	-$6.97 million	($0.64)	-3.55
Crescent Biopharma	$10.84 million	57.87	-$153.94 million	($6.72)	-2.51

XTL Biopharmaceuticals has higher earnings, but lower revenue than Crescent Biopharma. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Comparatively, 24.8% of Crescent Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares XTL Biopharmaceuticals and Crescent Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
Crescent Biopharma	N/A	-101.50%	-86.86%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for XTL Biopharmaceuticals and Crescent Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1	0	0	0	1.00
Crescent Biopharma	1	1	2	2	2.83

Crescent Biopharma has a consensus target price of $29.60, indicating a potential upside of 75.25%. Given Crescent Biopharma’s stronger consensus rating and higher probable upside, analysts clearly believe Crescent Biopharma is more favorable than XTL Biopharmaceuticals.

Risk & Volatility

XTL Biopharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, Crescent Biopharma has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.

Summary

Crescent Biopharma beats XTL Biopharmaceuticals on 8 of the 14 factors compared between the two stocks.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

About Crescent Biopharma

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.